newsfilter
← Latest News
GlobeNewswire·

iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

- 10 ongoing or planned clinical trials throughout 2023 to advance both differentiated clinical programs, anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant - EOS-984, a